630 related articles for article (PubMed ID: 20094957)
1. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
2. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
3. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
4. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Fléchon A; Boyle H; Négrier S
Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
6. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
9. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
10. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Gschwend J; Keilholz U
Aktuelle Urol; 2011 Jul; 42(4):242-6. PubMed ID: 21720974
[TBL] [Abstract][Full Text] [Related]
11. [Renal cell carcinoma].
Obara W; Fujioka T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology of renal cell carcinoma.
Mellado B; Gascón P
Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
[TBL] [Abstract][Full Text] [Related]
13. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
14. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Rini BI
Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
[TBL] [Abstract][Full Text] [Related]
15. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
17. [Effect of angiogenesis inhibitors on renal cell carcinoma].
Bodrogi I
Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
19. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
